Iron mobilisation and cellular protection by a new synthetic chelator O-Trensox

被引:37
作者
Rakba, N
Aouad, F
Henry, C
Caris, C
Morel, I
Baret, P
Pierre, JL
Brissot, P
Ward, RJ
Lescoat, G
Crichton, RR
机构
[1] Univ Catholique Louvain, Unite Biochim, B-1348 Louvain, Belgium
[2] INSERM U49, Unite Rech Hepatol, Rennes, France
[3] Univ Grenoble 1, Etud Dynam & Struct Select Lab, CNRS UMR 5616, F-38041 Grenoble, France
[4] Fac Pharm, INSERM U456, Rennes, France
[5] CHRU, Clin Malad Foie, Rennes, France
关键词
hepatocyte cultures; iron chelators; Fe-citrate; Fe-ferritin; O-Trensox;
D O I
10.1016/S0006-2952(98)00009-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We tested a new synthetic, 8-hydroxyquinoline-based, hexadentate iron chelator, O-Trensox and compared it with desferrioxamine B (DFO). Iron mobilisation was evaluated: (i) in vitro by using ferritin and haemosiderin; DFO mobilised iron much more rapidly from ferritin at pH 7.4 than did O-Trensox, whereas at pH 4, ferritin and haemosiderin iron mobilisation was very similar with both chelators; (ii) in vitro by using cultured rat hepatocytes which had been loaded with Fe-55-ferritin; here DFO was slightly more effective after 100 hr than O-Trensox; (iii) in vivo administration i.p. to rats which had been iron-loaded with iron dextran; O-Trensox mobilised 51.5% of hepatic iron over two weeks compared to 48.8% for DFO. We also demonstrated the effect of O-Trensox in decreasing the entry of Fe-55 citrate into hepatocyte cultures. The protective effect of O-Trensox against iron toxicity induced in hepatocyte cultures by ferric citrate was shown by decreased release of the enzymes lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotranferase (ALT) from the cultures and, using electron paramegnetic resonance (EPR) measurements, decreased production of lipid radicals. O-Trensox was more effective than DFO in quenching hydroxyl radicals in an acellular system. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:1797 / 1806
页数:10
相关论文
共 51 条
[31]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[32]   CHARACTERIZATION OF THE BINDING OF FERRITIN TO THE RAT-LIVER FERRITIN RECEPTOR [J].
MACK, U ;
STOREY, EL ;
POWELL, LW ;
HALLIDAY, JW .
BIOCHIMICA ET BIOPHYSICA ACTA, 1985, 843 (03) :164-170
[33]  
MACK U, 1983, J BIOL CHEM, V258, P4672
[34]  
McCance RA, 1937, LANCET, V2, P680
[35]   SURVIVAL AND CAUSES OF DEATH IN CIRRHOTIC AND IN NONCIRRHOTIC PATIENTS WITH PRIMARY HEMOCHROMATOSIS [J].
NIEDERAU, C ;
FISCHER, R ;
SONNENBERG, A ;
STREMMEL, W ;
TRAMPISCH, HJ ;
STROHMEYER, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (20) :1256-1262
[36]   IRON-CHELATION THERAPY WITH ORAL DEFERIPRONE IN PATIENTS WITH THALASSEMIA MAJOR [J].
OLIVIERI, NF ;
BRITTENHAM, GM ;
MATSUI, D ;
BERKOVITCH, M ;
BLENDIS, LM ;
CAMERON, RG ;
MCCLELLAND, RA ;
LIU, PP ;
TEMPLETON, DM ;
KOREN, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) :918-922
[37]  
Ritchie R. F., 1975, PLASMA PROTEINS, V2, P375
[38]  
SADDI R, 1974, CLIN GENET, V5, P234
[39]   PROTECTION AGAINST ACETAMINOPHEN-INDUCED LIVER-INJURY IN-VIVO BY AN IRON CHELATOR, DEFEROXAMINE [J].
SAKAIDA, I ;
KAYANO, K ;
WASAKI, S ;
NAGATOMI, A ;
MATSUMURA, Y ;
OKITA, K .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1995, 30 (01) :61-67
[40]   PREPARATION OF RAT-LIVER CELLS .3. ENZYMATIC REQUIREMENTS FOR TISSUE DISPERSION [J].
SEGLEN, PO .
EXPERIMENTAL CELL RESEARCH, 1973, 82 (02) :391-398